3-Bromomethcathinone (3-BMC) is a stimulant designer drug and monoamine releasing agent of the cathinone family. It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA), with values for induction of monoamine release of 136–137nM for serotonin, 25nM for norepinephrine, and 21–28nM for dopamine in rat brain synaptosomes. The drug produces hyperlocomotion in rodents comparably to but with slightly lower potency than methcathinone. The chemical synthesis of 3-BMC has been described. 3-BMC was first described in the scientific literature by 2002. It emerged as a novel designer drug in Israel and Germany and elsewhere in 2009.
See also Substituted cathinone 3-Fluoromethcathinone (3-FMC) 3-Chloromethcathinone (3-CMC; clophedrone) 3-Methylmethcathinone (3-MMC; metaphedrone) 4-Bromomethcathinone (4-BMC; brephedrone)
References
External links 3-Bromomethcathinone - Isomer Design